礼来以高达 25 亿美元的价格收购了 Scorpion 的癌症药物项目，扩大了其产品线。 Eli Lilly buys Scorpion's cancer drug program for up to $2.5 billion, expanding its pipeline.

Eli Lilly同意以最多25亿美元购买蝎子治疗疗程PI3Kα抑制剂方案,包括10亿美元的预付付款。 Eli Lilly has agreed to acquire Scorpion Therapeutics' PI3Kα inhibitor program for up to $2.5 billion, including a $1 billion upfront payment. 该方案包括STX-478,这是第1/2阶段乳腺癌试验中的药物。 The program includes STX-478, a drug in a Phase 1/2 trial for breast cancer. Lilly 将把 Scorpion 的其他资产分拆成一家新公司，由 Lilly 部分拥有并由 Scorpion 的管理层领导。 Lilly will spin out Scorpion's other assets into a new company, partially owned by Lilly and led by Scorpion's management. 此举支持莉莉利用其糖尿病和肥胖症药物的利润扩大其药物管道的战略。 This move supports Lilly's strategy to expand its drug pipeline using profits from its diabetes and obesity drugs.